Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL J SHAUGHNESSY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1316904550
CMS profile
150496
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$87,889.91

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL J SHAUGHNESSY

NPI 1316904550 · CMS profile ID 150496

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316904550?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL J SHAUGHNESSY, NPI 1316904550, CMS profile ID 150496. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316904550?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PAUL J SHAUGHNESSY, NPI 1316904550, CMS profile ID 150496. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316904550?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PAUL J SHAUGHNESSY, NPI 1316904550, CMS profile ID 150496, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316904550?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $87,889.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $218.8606/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644180 CMS
SANOFI-AVENTIS U.S. LLC $8,726.0006/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644182 CMS
SANOFI-AVENTIS U.S. LLC $121.8606/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644184 CMS
E.R. Squibb & Sons, L.L.C. $122.4206/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393302 CMS
E.R. Squibb & Sons, L.L.C. $1,141.5005/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393310 CMS
E.R. Squibb & Sons, L.L.C. $9.4705/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393308 CMS
bluebird bio, Inc. $149.3505/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1095479567 CMS
E.R. Squibb & Sons, L.L.C. $6,278.0005/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393300 CMS
GENZYME CORPORATION $143.1804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644134 CMS
E.R. Squibb & Sons, L.L.C. $121.7704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393294 CMS
E.R. Squibb & Sons, L.L.C. $307.2104/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393296 CMS
E.R. Squibb & Sons, L.L.C. $546.8304/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393298 CMS
E.R. Squibb & Sons, L.L.C. $663.6304/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393304 CMS
Astellas Pharma US Inc $94.9504/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139346366 CMS
Astellas Pharma US Inc $72.9904/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139346602 CMS
Celgene Corporation $300.0004/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101126728 CMS
E.R. Squibb & Sons, L.L.C. $1,779.0004/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101393284 CMS
Janssen Biotech, Inc. $121.8604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078756170 CMS
SANOFI-AVENTIS U.S. LLC $7,064.0003/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644136 CMS
SANOFI-AVENTIS U.S. LLC $128.3903/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644138 CMS
SANOFI-AVENTIS U.S. LLC $118.0003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644140 CMS
SANOFI-AVENTIS U.S. LLC $148.3602/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139644110 CMS
Takeda Pharmaceuticals U.S.A., Inc. $133.0602/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967483 CMS
Celgene Corporation $300.0002/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101126726 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,262.5002/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967475 CMS
Takeda Pharmaceuticals U.S.A., Inc. $442.9702/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967477 CMS
Takeda Pharmaceuticals U.S.A., Inc. $230.4602/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967479 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.0002/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $109,200.97 76
PY2020 $45,454.85 40
PY2021 $38,344.12 24
PY2022 $21,005.85 18
PY2023 $28,489.22 25
PY2024 $87,889.91 78
PY2025 $139,884.41 95

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $841,457.06 262
PY2024 Principal investigator $649,678.11 67
PY2023 Principal investigator $352,515.59 14
PY2022 Principal investigator $77,469.96 15
PY2021 Principal investigator $122,537.89 12
PY2020 Principal investigator $1,034,578.49 21
PY2019 Principal investigator $151,378.32 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

262 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $177.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319058
Principal investigator 1 Janssen Research & Development, LLC $450.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319065
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319163
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319240
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319396
Principal investigator 1 Janssen Research & Development, LLC $124.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319416
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319579
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319699
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319827
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320087
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320220
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320297
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320372
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320670
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320815
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320874
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320990
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321274
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321298
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321320
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321329
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321583
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321761
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321854
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321897
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322111
Principal investigator 1 Janssen Research & Development, LLC $450.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322137
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322294
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322495
Principal investigator 1 Janssen Research & Development, LLC $189.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322521
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322561
Principal investigator 1 Janssen Research & Development, LLC $189.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322896
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323138
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323155
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323456
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323527
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323982
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324379
Principal investigator 1 Janssen Research & Development, LLC $450.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324631
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324755
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324902
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325076
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325861
Principal investigator 1 Janssen Research & Development, LLC $1,300.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326235
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326273
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326366
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326443
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326475
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326602
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322119
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323511
Principal investigator 1 Janssen Research & Development, LLC $148.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324169
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324885
Principal investigator 1 Janssen Research & Development, LLC $187.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320774
Principal investigator 1 Janssen Research & Development, LLC $13,917.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322308
Principal investigator 1 Janssen Research & Development, LLC $187.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322324
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323713
Principal investigator 1 Janssen Research & Development, LLC $148.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325756
Principal investigator 1 Kite Pharma, Inc. $3,000.00 12/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070331
Principal investigator 1 Kite Pharma, Inc. $3,000.00 12/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070335
Principal investigator 1 Kite Pharma, Inc. $3,000.00 12/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070776
Principal investigator 1 Kite Pharma, Inc. $1,567.00 12/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070780
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,975.00 12/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1235993821
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319074
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320737
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322637
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323190
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323359
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323704
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324273
Principal investigator 1 Janssen Research & Development, LLC $38.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324808
Principal investigator 1 Autolus Inc $2,000.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667936
Principal investigator 1 Autolus Inc $2,000.00 11/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668270
Principal investigator 1 Kite Pharma, Inc. $3,000.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070322
Principal investigator 1 Kite Pharma, Inc. $3,749.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070327
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325627
Principal investigator 1 Autolus Inc $1,000.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668128
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319595
Principal investigator 1 Janssen Research & Development, LLC $115.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324546
Principal investigator 1 Autolus Inc $5,123.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668018
Principal investigator 1 Autolus Inc $2,000.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668196
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,831.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) No dispute reported 06/30/2026 1235993823
Principal investigator 1 Kite Pharma, Inc. $3,000.00 10/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070771
Principal investigator 1 Novartis Pharmaceuticals Corporation $143.18 10/27/2025 Non-covered Recipient Entity
METHODIST HEALTHCARE SYSTEM
Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy No dispute reported 06/30/2026 1190313825
Principal investigator 1 National Marrow Donor Program $1,000.00 10/24/2025 Covered Recipient Teaching Hospital
Methodist Hospital
A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research No dispute reported 06/30/2026 1249325581
Principal investigator 1 Kite Pharma, Inc. $3,000.00 10/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070767
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319388
Principal investigator 1 Autolus Inc $1,000.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667878
Principal investigator 1 Kite Pharma, Inc. $3,000.00 10/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070319
Principal investigator 1 Janssen Research & Development, LLC $187.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319277
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321377
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323110
Principal investigator 1 Autolus Inc $65.80 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667934
Principal investigator 1 Autolus Inc $315.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668148
Principal investigator 1 Janssen Research & Development, LLC $525.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322903
Principal investigator 1 Autolus Inc $2,000.00 09/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667854
Principal investigator 1 Kite Pharma, Inc. $3,000.00 09/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070314
Principal investigator 1 Autolus Inc $2,000.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668188
Principal investigator 1 Kite Pharma, Inc. $3,000.00 09/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070760
Principal investigator 1 Kite Pharma, Inc. $3,000.00 08/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070311
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,765.00 08/26/2025 Non-covered Recipient Entity
METHODIST HEALTH CARE SYSTEM
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA) No dispute reported 06/30/2026 1190302707
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,558.75 08/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190312325
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322175
Principal investigator 1 Autolus Inc $14,040.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668076
Principal investigator 1 Autolus Inc $15,696.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668078
Principal investigator 1 Autolus Inc $343.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668080
Principal investigator 1 Autolus Inc $6,510.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668082
Principal investigator 1 Autolus Inc $18,030.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668084
Principal investigator 1 Autolus Inc $18,287.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668086
Principal investigator 1 Autolus Inc $265.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668088
Principal investigator 1 Autolus Inc $265.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668218
Principal investigator 1 Autolus Inc $2,000.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668220
Principal investigator 1 Kite Pharma, Inc. $3,000.00 08/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070756
Principal investigator 1 Autolus Inc $1,191.67 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667994
Principal investigator 1 Autolus Inc $188.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667858
Principal investigator 1 Autolus Inc $2,178.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667860
Principal investigator 1 Autolus Inc $6,238.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667862
Principal investigator 1 Autolus Inc $10,875.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667864
Principal investigator 1 Autolus Inc $12,923.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667866
Principal investigator 1 Autolus Inc $14,414.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667868
Principal investigator 1 Autolus Inc $8,925.00 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667870
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325251
Principal investigator 1 Kite Pharma, Inc. $2,218.00 07/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070307
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323548
Principal investigator 1 Kite Pharma, Inc. $5,000.00 07/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070302
Principal investigator 1 Autolus Inc $1,779.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668034
Principal investigator 1 Autolus Inc $15,922.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668036
Principal investigator 1 Autolus Inc $9,484.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668038
Principal investigator 1 Autolus Inc $11,285.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668040
Principal investigator 1 Autolus Inc $17,366.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668042
Principal investigator 1 Autolus Inc $12,476.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668044
Principal investigator 1 Autolus Inc $284.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668048
Principal investigator 1 Autolus Inc $189.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668050
Principal investigator 1 Autolus Inc $1,250.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668052
Principal investigator 1 Autolus Inc $60.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668054
Principal investigator 1 Autolus Inc $125.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668056
Principal investigator 1 Autolus Inc $44.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668058
Principal investigator 1 Autolus Inc $188.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668064
Principal investigator 1 Autolus Inc $284.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668198
Principal investigator 1 Autolus Inc $189.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668200
Principal investigator 1 Autolus Inc $284.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668202
Principal investigator 1 Autolus Inc $284.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668204
Principal investigator 1 Autolus Inc $189.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668206
Principal investigator 1 Autolus Inc $60.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668208
Principal investigator 1 Autolus Inc $125.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668210
Principal investigator 1 Autolus Inc $125.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668212
Principal investigator 1 Autolus Inc $189.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668214
Principal investigator 1 Kite Pharma, Inc. $3,000.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070298
Principal investigator 1 Kite Pharma, Inc. $3,000.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070752
Principal investigator 1 Janssen Research & Development, LLC $4,564.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321678
Principal investigator 1 Autolus Inc $66.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667938
Principal investigator 1 Autolus Inc $1,231.60 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667942
Principal investigator 1 Autolus Inc $66.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668150
Principal investigator 1 Autolus Inc $2,000.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668152
Principal investigator 1 Autolus Inc $2,000.00 06/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667908
Principal investigator 1 Kite Pharma, Inc. $900.00 06/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070294
Principal investigator 1 Kite Pharma, Inc. $3,000.00 06/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070290
Principal investigator 1 Kite Pharma, Inc. $3,000.00 06/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070748
Principal investigator 1 Janssen Research & Development, LLC $4,564.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321125
Principal investigator 1 Autolus Inc $349.77 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667828
Principal investigator 1 Autolus Inc $8,265.00 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667830
Principal investigator 1 Kite Pharma, Inc. $7,262.00 05/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070286
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 05/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325001
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667874
Principal investigator 1 Autolus Inc $283.92 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667876
Principal investigator 1 Autolus Inc $125.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667892
Principal investigator 1 Autolus Inc $1,113.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668132
Principal investigator 1 Autolus Inc $48.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668136
Principal investigator 1 Autolus Inc $58.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668138
Principal investigator 1 Autolus Inc $189.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668140
Principal investigator 1 Autolus Inc $60.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668142
Principal investigator 1 Autolus Inc $48.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668228
Principal investigator 1 Autolus Inc $58.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668230
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668234
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668236
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668238
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668240
Principal investigator 1 Autolus Inc $188.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668242
Principal investigator 1 Celgene Corporation $6,809.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) No dispute reported 06/30/2026 1222306819
Principal investigator 1 Kite Pharma, Inc. $980.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070273
Principal investigator 1 Kite Pharma, Inc. $3,000.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070277
Principal investigator 1 Kite Pharma, Inc. $1,500.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070281
Principal investigator 1 Kite Pharma, Inc. $2,290.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070736
Principal investigator 1 Kite Pharma, Inc. $1,500.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070740
Principal investigator 1 Kite Pharma, Inc. $3,000.00 05/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070745
Principal investigator 1 Janssen Research & Development, LLC $4,564.00 05/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321200
Principal investigator 1 Autolus Inc $2,000.00 04/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668268
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325786
Principal investigator 1 Kite Pharma, Inc. $3,000.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070269
Principal investigator 1 Autolus Inc $3,873.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667914
Principal investigator 1 Autolus Inc $1,986.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667916
Principal investigator 1 Autolus Inc $10,069.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667918
Principal investigator 1 Autolus Inc $40.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667920
Principal investigator 1 Autolus Inc $1,250.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667922
Principal investigator 1 Autolus Inc $33,782.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667924
Principal investigator 1 Autolus Inc $14,585.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667926
Principal investigator 1 Autolus Inc $2,731.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667928
Principal investigator 1 Kite Pharma, Inc. $3,000.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070732
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 03/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322300
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 03/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323620
Principal investigator 1 Autolus Inc $26,563.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667842
Principal investigator 1 Autolus Inc $689.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667844
Principal investigator 1 Autolus Inc $25,199.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667912
Principal investigator 1 Kite Pharma, Inc. $3,000.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070266
Principal investigator 1 Kite Pharma, Inc. $3,000.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070728
Principal investigator 1 Autolus Inc $3,873.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668098
Principal investigator 1 Autolus Inc $44.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668100
Principal investigator 1 Autolus Inc $60.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668102
Principal investigator 1 Autolus Inc $188.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668104
Principal investigator 1 Autolus Inc $58.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668106
Principal investigator 1 Autolus Inc $48.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668108
Principal investigator 1 Autolus Inc $500.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668110
Principal investigator 1 Autolus Inc $660.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668116
Principal investigator 1 Autolus Inc $2,150.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668118
Principal investigator 1 Autolus Inc $1,030.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668120
Principal investigator 1 Autolus Inc $188.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668222
Principal investigator 1 Autolus Inc $2,000.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668226
Principal investigator 1 Kite Pharma, Inc. $3,000.00 03/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070262
Principal investigator 1 Autolus Inc $1,113.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667944
Principal investigator 1 Autolus Inc $48.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667950
Principal investigator 1 Autolus Inc $58.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667952
Principal investigator 1 Autolus Inc $283.75 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667954
Principal investigator 1 Autolus Inc $40.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667956
Principal investigator 1 Autolus Inc $189.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667958
Principal investigator 1 Autolus Inc $60.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667960
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667962
Principal investigator 1 Autolus Inc $1,000.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667964
Principal investigator 1 Autolus Inc $1,094.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667966
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668154
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668156
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668158
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668160
Principal investigator 1 Autolus Inc $125.00 03/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668162
Principal investigator 1 Autolus Inc $6,645.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667900
Principal investigator 1 Autolus Inc $3,000.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667904
Principal investigator 1 Autolus Inc $2,000.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668254
Principal investigator 1 Celgene Corporation $63,458.70 02/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) No dispute reported 06/30/2026 1222305474
Principal investigator 1 Janssen Research & Development, LLC $175.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319028
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320119
Principal investigator 1 Janssen Research & Development, LLC $38.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321101
Principal investigator 1 Janssen Research & Development, LLC $175.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321578
Principal investigator 1 Janssen Research & Development, LLC $189.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322396
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 02/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325427
Principal investigator 1 Janssen Research & Development, LLC $10,003.00 02/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325188
Principal investigator 1 Autolus Inc $2,000.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668190
Principal investigator 1 Kite Pharma, Inc. $3,000.00 02/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070258
Principal investigator 1 Kite Pharma, Inc. $3,000.00 02/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070720
Principal investigator 1 Kite Pharma, Inc. $3,000.00 02/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212070724
Principal investigator 1 Celgene Corporation $21,832.50 01/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1222306701
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321177
Principal investigator 1 Celgene Corporation $2,694.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1222306221
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,626.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190304483
Principal investigator 1 Autolus Inc $12,000.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243667998
Principal investigator 1 Autolus Inc $2,980.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668000
Principal investigator 1 Autolus Inc $48.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668002
Principal investigator 1 Autolus Inc $58.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668004
Principal investigator 1 Autolus Inc $283.75 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668006
Principal investigator 1 Autolus Inc $189.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668008
Principal investigator 1 Autolus Inc $60.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668010
Principal investigator 1 Autolus Inc $188.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668012
Principal investigator 1 Autolus Inc $266.67 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AUTO1-AL1 No dispute reported 06/30/2026 1243668014
Principal investigator 1 Kite Pharma, Inc. $3,000.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212070254